133 related articles for article (PubMed ID: 27059191)
1. The Cost of Initial Care for Medicare Patients With Advanced Ovarian Cancer.
Urban RR; He H; Alfonso-Cristancho R; Hardesty MM; Goff BA
J Natl Compr Canc Netw; 2016 Apr; 14(4):429-37. PubMed ID: 27059191
[TBL] [Abstract][Full Text] [Related]
2. The end of life costs for Medicare patients with advanced ovarian cancer.
Urban RR; He H; Alfonso R; Hardesty MM; Goff BA
Gynecol Oncol; 2018 Feb; 148(2):336-341. PubMed ID: 29208368
[TBL] [Abstract][Full Text] [Related]
3. Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.
Schwartz KL; Simon MS; Bylsma LC; Ruterbusch JJ; Beebe-Dimmer JL; Schultz NM; Flanders SC; Barlev A; Fryzek JP; Quek RGW
Cancer; 2018 May; 124(10):2104-2114. PubMed ID: 29505670
[TBL] [Abstract][Full Text] [Related]
4. Costs of treatment for elderly women with advanced ovarian cancer in a Medicare population.
Forde GK; Chang J; Ziogas A; Tewari K; Bristow RE
Gynecol Oncol; 2015 Jun; 137(3):479-84. PubMed ID: 25866323
[TBL] [Abstract][Full Text] [Related]
5. Impact of Nonconcordance With NCCN Guidelines on Resource Utilization, Cost, and Mortality in De Novo Metastatic Breast Cancer.
Rocque GB; Williams CP; Jackson BE; Ingram SA; Halilova KI; Pisu M; Kenzik KM; Azuero A; Forero A; Bhatia S
J Natl Compr Canc Netw; 2018 Sep; 16(9):1084-1091. PubMed ID: 30181420
[No Abstract] [Full Text] [Related]
6. Simulated Costs of the ASCO Patient-Centered Oncology Payment Model in Medicare Beneficiaries With Newly Diagnosed Advanced Ovarian Cancer.
Moss HA; Havrilesky LJ; Wang FF; Georgieva MV; Hendrix LH; Dinan MA
J Oncol Pract; 2019 Dec; 15(12):e1018-e1027. PubMed ID: 31613721
[TBL] [Abstract][Full Text] [Related]
7. Concordance with NCCN treatment guidelines: Relations with health care utilization, cost, and mortality in breast cancer patients with secondary metastasis.
Rocque GB; Williams CP; Kenzik KM; Jackson BE; Azuero A; Halilova KI; Ingram SA; Pisu M; Forero A; Bhatia S
Cancer; 2018 Nov; 124(21):4231-4240. PubMed ID: 30317547
[TBL] [Abstract][Full Text] [Related]
8. Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer.
Brown ML; Riley GF; Potosky AL; Etzioni RD
Med Care; 1999 Dec; 37(12):1249-59. PubMed ID: 10599606
[TBL] [Abstract][Full Text] [Related]
9. Ovarian cancer outcomes: Predictors of early death.
Urban RR; He H; Alfonso R; Hardesty MM; Gray HJ; Goff BA
Gynecol Oncol; 2016 Mar; 140(3):474-80. PubMed ID: 26743531
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of trends in the cost of initial cancer treatment.
Warren JL; Yabroff KR; Meekins A; Topor M; Lamont EB; Brown ML
J Natl Cancer Inst; 2008 Jun; 100(12):888-97. PubMed ID: 18544740
[TBL] [Abstract][Full Text] [Related]
11. Trends in treatment of advanced epithelial ovarian cancer in the Medicare population.
Thrall MM; Gray HJ; Symons RG; Weiss NS; Flum DR; Goff BA
Gynecol Oncol; 2011 Jul; 122(1):100-6. PubMed ID: 21496889
[TBL] [Abstract][Full Text] [Related]
12. Population-Based Analysis of Patient Age and Other Disparities in the Treatment of Ovarian Cancer in Central Appalachia and Kentucky.
Ore RM; Chen Q; DeSimone CP; Miller RW; Baldwin LA; van Nagell JR; Huang B; Tucker TC; Johnson MS; Fredericks TI; Ueland FR
South Med J; 2018 Jun; 111(6):333-341. PubMed ID: 29863220
[TBL] [Abstract][Full Text] [Related]
13. Cost-utility analysis of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer.
Lairson DR; Parikh RC; Cormier JN; Du XL
Value Health; 2014; 17(1):34-42. PubMed ID: 24438715
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Neoadjuvant Chemotherapy versus Primary Surgery in Elderly Patients with Advanced Ovarian Cancer.
Poonawalla IB; Lairson DR; Chan W; Piller LB; Du XL
Value Health; 2015 Jun; 18(4):387-95. PubMed ID: 26091592
[TBL] [Abstract][Full Text] [Related]
15. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.
Davis KL; Goyal RK; Able SL; Brown J; Li L; Kaye JA
Lung Cancer; 2015 Feb; 87(2):176-85. PubMed ID: 25532680
[TBL] [Abstract][Full Text] [Related]
16. Socioeconomic status as a predictor of adherence to treatment guidelines for early-stage ovarian cancer.
Hodeib M; Chang J; Liu F; Ziogas A; Dilley S; Randall LM; Anton-Culver H; Bristow RE
Gynecol Oncol; 2015 Jul; 138(1):121-7. PubMed ID: 25913132
[TBL] [Abstract][Full Text] [Related]
17. Treatment Patterns, Outcomes, and Costs for Bowel Obstruction in Ovarian Cancer.
Suidan RS; He W; Sun CC; Zhao H; Ramondetta LM; Badgwell BD; Bodurka DC; Lu KH; Giordano SH; Meyer LA
Int J Gynecol Cancer; 2017 Sep; 27(7):1350-1359. PubMed ID: 28574929
[TBL] [Abstract][Full Text] [Related]
18. Costs of Cancer Care Across the Disease Continuum.
Kaye DR; Min HS; Herrel LA; Dupree JM; Ellimoottil C; Miller DC
Oncologist; 2018 Jul; 23(7):798-805. PubMed ID: 29567821
[TBL] [Abstract][Full Text] [Related]
19. Healthcare Utilization and Costs During the Initial Phase of Care Among Elderly Women With Breast Cancer.
Vyas A; Madhavan SS; Sambamoorthi U; Pan XL; Regier M; Hazard H; Kalidindi S
J Natl Compr Canc Netw; 2017 Nov; 15(11):1401-1409. PubMed ID: 29118232
[No Abstract] [Full Text] [Related]
20. Esophageal cancer treatment costs by phase of care and treatment modality, 2000-2013.
Tramontano AC; Chen Y; Watson TR; Eckel A; Hur C; Kong CY
Cancer Med; 2019 Sep; 8(11):5158-5172. PubMed ID: 31347306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
